Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Respiratory Clinical Trials Research & Development

AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet

  • Analysis

Executive Summary

AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.

You may also be interested in...



HES Flare: GSK's Nucala Edges Forward

GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.

GSK Puts Faith In Next Gen Respiratory, Real World Studies

A pioneer in the field, can GSK’s investment in real world studies pay off?

Blow To AZ As FDA Rejects COPD Contender

Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.

Table

View full table

Related Content

Pink Sheet
Scrip

Topics

Related Companies

Tags:
Respiratory Clinical Trials Research & Development
Latest News

Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

Patent Settlements and Medicare Negotiation: What Leverage Does Pharma Have To ‘Game’ Price Reform?

GSK Makes ADC Pipeline Comeback With Mersana Deal

New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data

See All
UsernamePublicRestriction

Register

SC125933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By